« Previous
Next »
Titles
- Tax administration: IRS oversight of hospitals’ tax-exempt status : testimony before the Subcommittee on Oversight, Committee on Ways and Means, House of Representatives1
- Technical assistance brief: implementation of inflation-indexed rebates for Part B drugs1
- Technical considerations for medical devices with physiologic closed-loop control technology: guidance for industry and Food and Drug Administration staff1
- Telehealth was critical for providing services to Medicare beneficiaries during the first year of the COVID-19 pandemic1
- Testing of glycerin, propylene glycol, maltitol solution, hydrogenated starch hydrolysate, sorbitol solution, and other high-risk drug components for diethylene glycol and ethylene glycol: guidance for industry1
- The Food and Drug Administration needs to improve the premarket tobacco application review process for electronic nicotine delivery systems to protect public health1
- The Provider Relief Fund helped select nursing homes maintain services during the COVID-19 pandemic, but some found guidance difficult to use1
- The Strategic National Stockpile was not positioned to respond effectively to the COVID-19 pandemic1
- The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern1
- The future of remote patient monitoring1
- The risk of misuse and diversion of buprenorphine for opioid use disorder appears to be low in Medicare Part D1
- The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 20221
- Tobacco products: principles for designing and conducting tobacco product perception and intention studies1
- Toolkit: analyzing telehealth claims to assess program integrity risks1
- Tracking the funds. Specific fiscal year 2023 provisions for the Office of National Drug Control Policy1
- Tracking the funds: specific fiscal year 2022 provisions for Department of Health and Human Services : report to congressional committees1
- Transition plan for medical devices issued emergency use authorizations (EUAs) related to coronavirus disease 2019 (COVID-19): guidance for industry, other stakeholders, and Food and Drug Administration staff1
- Transition plan for medical devices that fall within enforcement policies issued during the coronavirus disease 2019 (COVID-19) public health emergency: guidance for industry, other stakeholders, and Food and Drug Administration staff1
- Tribal epidemiology centers: HHS actions needed to enhance data access : report to congressional addressees1